Clinical trial NCT03919669: A Longitudinal Evaluation of a Radiotracer for Use in Tau Tracking
Official title: Longitudinal Evaluation of [18-F]MK-6240 as a Novel Tau PET Radiotracer in Patients With Alzheimer's Disease Dementia or Mild Cognitive Impairment Compared to Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Alzheimer Disease
Mild Cognitive Impairment
Lead sponsor: University of Wisconsin, Madison
Sponsor class: OTHER
Collaborators: name: Cerveau Technologies, Inc.
First posted: 2019-04-18
Enrollment: 27
Sex: ALL
Minimum age (years): 50
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This is a longitudinal, observational study evaluating the imaging characteristics of the tau PET radioligand \[18F\]MK-6240 in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and Healthy Volunteer (HV) subjects. Up to 42 subjects, including approximately 28 MCI/mild AD subjects, up to 5 moderate AD subjects, and 9 similarly aged HV subjects will be consented and screened. Imaging procedures include \[11C\]PiB to evaluate amyloid deposition, \[18F\]MK-6240 PET, and structural MRI. All subjects complete an evaluable baseline \[18F\]MK-6240 PET scan, as well as scans at 6, 12 and 24 months post-baseline. If unable to complete the 6 month, 12 month, or 24 month visit, an 18 month and/or 30 month visit may instead be scheduled, totaling a maximum of four time points.


Eligibility criteria: Inclusion Criteria for all subjects:

* Signed and dated written informed consent must be obtained from the subject to enter the study and before any assessment is performed.
* Pregnancy: Participant is not pregnant at the time of the PET and MRI imaging exams. Urine pregnancy tests will be conducted as needed with pre-menopausal women who are of child-bearing potential.
* Willing and able to undergo study procedures and study schedule
* Availability of a study partner who has frequent and sufficient contact with the subject and is able to provide accurate information regarding the subject's cognitive and functional abilities for the CDR, agrees to accompany the subject and provide information at visits or is available by phone. The study partner must have sufficient cognitive capacity, in the judgment of the investigator, to accurately report upon the subject's behavior and cognitive and functional abilities.
* Healthy with no clinically relevant finding on physical examination at screening and upon reporting for the Baseline \[18F\]MK-6240 imaging visit.

Inclusion Criteria for Healthy Volunteers

* Normal Cognition based on cognitive results at screening.
* Healthy with no clinically relevant finding on physical examination at screening and upon reporting for the Baseline \[18F\]MK-6240 imaging visit.
* CDR global score =0

Inclusion Criteria for Subjects with a Diagnosis of MCI or Dementia Due to AD

* Have screening \[11C\]PiB PET imaging demonstrating amyloid binding based on qualitative read or DVR index value \>1.20.
* MMSE score 26-30 (inclusive), CDR global score 0.5 for subjects with MCI
* MMSE score 22-26 (inclusive), CDR global score 0.5 or 1 for subjects with mild dementia due to AD
* MMSE score 16-21 (inclusive), CDR global score 1-2 for subjects with moderate dementia due to AD
* Subjects with MCI must meet 2018 research criteria for MCI (Jack et al., 2018).
* Subjects with dementia must meet 2018 research criteria for dementia (Jack et al., 2018).
* A structural brain MRI with no evidence of non-AD disease to account for dementia or MRI exclusion criteria.

Exclusion Criteria for all subjects

* Lack of capacity to provide informed consent at study entry.
* Subject has received an investigational drug or device within 30 days of screening. Other experimental PET radiotracer drugs are not excluded.
* For women, pregnant, lactating or breastfeeding or intention to become pregnant.
* Evidence of unstable or untreated clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, alternative neurological, immunodeficiency, pulmonary, or other disorder or disease. Stable, treated chronic medical conditions like hypertension, hypercholesterolemia, diabetes mellitus, non-metastatic dermatologic or prostatic cancer, etc. are acceptable as long as they do not, in the study investigator's opinion, contribute to cognitive dysfunction or limit participation in study procedures.
* Any illness or other consideration that makes it unlikely that the subject will be able to complete the 26-month study.
* Current or prior history (within past 5 years) of significant alcohol or substance abuse as determined by the investigator.
* Psychiatric disorders that may interfere with the study including current major Axis I DSM-V disorders including but not limited to severe Major depression, current or history of bipolar I disorder, or schizophrenia.
* Non-English speakers or subjects who are unable to comprehend study materials are excluded at entry
* MRI exclusion criteria include: Findings that may be responsible for neurologic status of the subject such as significant evidence of cerebrovascular disease with multiple infarcts, infectious disease, space-occupying lesion, normal pressure hydrocephalus, CNS trauma, or any other structural abnormality that may impact cognition or image analysis, as judged by the investigator.
* MRI-incompatible implants or devices such as certain cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips and other medical implants that have not been certified for MRI, or history of claustrophobia in MRI that prevents completion of MRI protocol.
* Treatment with any therapeutic molecule that targets Aβ or tau within 12 months prior to screening.

Primary outcomes:
measure: Change in [18F]MK-6240 Standard Uptake Value Ratio (SUVR) Uptake
timeFrame: Baseline to 12 months
Secondary outcomes:
measure: The Correlation Between the Change in [18F]MK-6240 Uptake and the Change in the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) Using Items 1-11
timeFrame: Baseline to 12 months
measure: Correlate the Changes in [18F]MK-6240 Uptake and Changes in Clinical Cognitive Assessments by Clinical Dementia Rating Scale (CDR).
timeFrame: Baseline to 12 months
measure: Correlate the Changes in [18F]MK-6240 Uptake and Changes in Clinical Cognitive Assessments by Mini-Mental Status Exam (MMSE)
timeFrame: Baseline to 12 months
measure: Change in [18F]MK-6240 Standard Uptake Value Ratio (SUVR) Uptake
timeFrame: Baseline to 24 months
measure: Change in [18F]MK-6240 Standard Uptake Value Ratio (SUVR) Uptake
timeFrame: Baseline to 6 months
Other outcomes:
Locations:
city: Madison
country: United States
facility: University of Wisconsin-Madison
state: Wisconsin
Study officials:
References: